Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Chinese SLE Treatment And Research Group
- Target Recruit Count
- 146
- Registration Number
- NCT04582136
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- AgelessRx
- Target Recruit Count
- 129
- Registration Number
- NCT04488601
- Locations
- 🇺🇸
AgelessRx, Chicago, Illinois, United States
Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS
- Conditions
- Interventions
- Locations
- 🇺🇸
University Hospital System, San Antonio, Texas, United States
🇺🇸Audie L Murphy Memorial Veterans Hospital, San Antonio, Texas, United States
Haplo Peripheral Blood Sct In GVHD Prevention
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Zachariah Michael DeFilipp
- Target Recruit Count
- 25
- Registration Number
- NCT04473911
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Emory University
- Target Recruit Count
- 50
- Registration Number
- NCT04469530
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Aflac Cancer & Blood Disorders Centers, Atlanta, Georgia, United States
🇺🇸Texas Children's Cancer Center, Houston, Texas, United States
Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA
- Conditions
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Bing Han
- Target Recruit Count
- 56
- Registration Number
- NCT04470804
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Efficacy and Safety of Sirolimus in COVID-19 Infection
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 40
- Registration Number
- NCT04461340
- Locations
- 🇪🇬
Faculty of Medicine, Alexandria university, Egypt, Alexandria, Egypt
Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma
- Conditions
- Interventions
- First Posted Date
- 2020-06-26
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Children's Hospital of Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT04448873
- Locations
- 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China
Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Prevail Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT04411654
- Locations
- 🇬🇧
Manchester Centre for Genomic Medicine, 6th Floor, St Mary's Hospital, Oxford Road, Manchester, United Kingdom
🇺🇸UCSF Benioff Children's Hospital, 5700 Martin Luther King Jr Way, Oakland, California, United States
🇺🇸University of Minnesota Masonic Children's Hospital, 2450 Riverside Avenue, Minneapolis, Minnesota, United States
Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 30
- Registration Number
- NCT04370795
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.